Bobby Malik, MD
Internal Medicine · Chesterfield, MONPI 1396804712
Payments from drug & device makers
Across 502 payments — averaging $12.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$791
- Novo Nordisk$737
- AstraZeneca$650
- Amarin Pharma, Inc.$548
- Amgen$511
- Boehringer Ingelheim$423
- plus $3K from 27 others
What the payments were for
- Food & beverage$6,375100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 69 | $791 |
| Novo Nordisk | 62 | $737 |
| AstraZeneca | 47 | $650 |
| Amarin Pharma, Inc. | 47 | $548 |
| Amgen(2 entities) | 41 | $511 |
| Boehringer Ingelheim | 38 | $423 |
| Lilly USA, LLC | 33 | $390 |
| Kowa Pharmaceuticals America, Inc. | 30 | $383 |
| Pfizer | 23 | $205 |
| Sanofi-aventis U.S. LLC | 14 | $189 |
| Johnson & Johnson | 11 | $183 |
| Abbott | 3 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $160 |
| Teva Pharmaceuticals USA, Inc. | 10 | $146 |
| Merck | 10 | $139 |
| Abiomed | 2 | $89 |
| Arbor Pharmaceuticals, Inc. | 6 | $86 |
| Daiichi Sankyo Inc. | 6 | $84 |
| IBSA Pharma Inc. | 6 | $77 |
| Avanir Pharmaceuticals, Inc. | 5 | $69 |
| Astellas Pharma US Inc | 4 | $52 |
| Novartis | 3 | $43 |
| GSK | 3 | $38 |
| Scilex Pharmaceuticals Inc. | 3 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Strongbridge US Inc. | 2 | $27 |
| Eisai Inc. | 2 | $24 |
| Boston Scientific | 1 | $20 |
| Medicure Pharma Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENSITE PRECISION$112
How this compares
$6,375 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 860 | $247,522 |
| Austedo XrDeutetrabenazine | 38 | $184,903 |
| Invega SustennaPaliperidone Palmitate | 24 | $84,282 |
| XareltoRivaroxaban | 213 | $61,127 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $50,959 |
| TrulicityDulaglutide | 55 | $43,508 |
| MyrbetriqMirabegron | 153 | $37,154 |
| FanaptIloperidone | 26 | $31,530 |
| NuedextaDextromethorphan Hbr/Quinidine | 39 | $25,824 |
| EntrestoSacubitril/Valsartan | 79 | $24,312 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $21,959 |
| JardianceEmpagliflozin | 70 | $21,879 |
| LinzessLinaclotide | 33 | $20,093 |
| JanuviaSitagliptin Phosphate | 68 | $19,806 |
| Divalproex Sodium | 294 | $19,622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $205 | $247,522860 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $146 | $184,90338 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $183 | $145,409237 claims |
| AbbVieLinzess, Vraylar, Restasis, Creon | $791 | $67,512115 claims |
| GileadBiktarvy | $14 | $50,95912 claims |
| Lilly USA, LLCTrulicity | $390 | $43,50855 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta | $38 | $43,25798 claims |
| Astellas Pharma US IncMyrbetriq | $52 | $37,154153 claims |
| Boehringer IngelheimJardiance, Tradjenta | $423 | $36,651127 claims |
| AstraZenecaLokelma, Farxiga | $650 | $32,84698 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $69 | $25,82439 claims |
| NovartisEntresto | $43 | $24,31279 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Chesterfield
- Jianbo WangChesterfield$643K
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.